论文部分内容阅读
目的 探讨P5 3突变在胶质瘤发生发展中的作用及其与临床病理特征和预后的关系。方法 利用聚合酶链反应 -单链构象多态性分析 (PCR -SSCP)及LSAB免疫组化法对已明确诊断的 4 8例脑胶质瘤进行P5 3基因突变以及蛋白表达的检测。结果 4 8例胶质瘤中 2 0例P5 3蛋白呈阳性表达 (4 1.7% )。在高级别的肿瘤 (Ⅲ、Ⅳ级 )中P5 3表达率明显高于低级别 (Ⅰ、Ⅱ级 )的肿瘤 (分别是 6 3.2 %、2 7.6 % ) (P <0 .0 5 )。PCR -SSCP检测发现 17例 (35 .4 % )呈现P5 3基因的单链构象多态性改变 ,均位于 5 - 8外显子 ,突变例数依次为 7(4 1.2 % )、1(5 .9% )、4 (2 3.5 % )、5 (2 9.4 % )。两种方法检测的符合率为 89.6 % (4 3/4 8)。在单因素分析中P5 3突变与预后相关 ,而在多因素分析中P5 3突变与预后无关 ,肿瘤的组织学分级与预后相关性显著。该基因的突变与患者年龄、肿瘤大小、性别无关 ,但与胶质瘤的恶性程度相关性显著。结论 胶质瘤中P5 3突变多发于第 5、7、8外显子 ,该基因的突变与胶质瘤的发生及恶性进展相关 ,与预后无关。
Objective To investigate the role of P53 mutation in the development of glioma and its relationship with clinicopathological features and prognosis. Methods P5 3 gene mutation and protein expression were detected in 48 diagnosed gliomas by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and LSAB immunohistochemistry. Results 20 cases of P5 3 protein in 48 gliomas were positive (4 1.7%). The expression of P53 in high-grade tumors (Ⅲ, Ⅳ grade) was significantly higher than that of low-grade tumors (6 3.2%, 2 7.6% respectively) (P <0.05). The results of PCR-SSCP showed that single-stranded conformational polymorphism of P5 3 gene was detected in 17 cases (35.4%), which were all located in exon 5-8 with 7 (4 1.2%) and 1 (5 .9%), 4 (23.5%), 5 (2 9.4%). The coincidence rate of the two methods was 89.6% (4 3/4 8). In univariate analysis, P5 3 mutation was associated with prognosis. However, in the multivariate analysis, P5 3 mutation had no relationship with prognosis, and the histological grade was significantly correlated with prognosis. The mutation of the gene has nothing to do with the patient’s age, tumor size and gender, but it has significant correlation with the malignant degree of glioma. Conclusion The P5 3 mutation in gliomas is more frequent in exon 5, exon 7 and exon 7. The mutation of this gene is associated with the development of malignant gliomas and has no relation with the prognosis.